Form 4: Dianthus Therapeutics Executive Adam M. Veness Reports Stock Option Grant

Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, reported the acquisition of stock options for 100,000 shares of common stock.

Summary

• On February 3, 2025, Adam M. Veness, SVP, General Counsel and Secretary of Dianthus Therapeutics, Inc., was granted stock options to purchase 100,000 shares of the company's common stock.
• The exercise price of the options is $22.07 per share.
• The options vest in equal monthly installments over four years, starting January 1, 2025, contingent upon continued service to the Issuer.
• The expiration date for the options is February 2, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.

Positives

• The grant of stock options to a key executive like Adam M. Veness aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. This grant aligns with standard compensation practices in the sector.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Amgen, Regeneron, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule of four years with monthly installments is a typical arrangement.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's performance.
• Employees may see this as a sign of stability and potential growth within the company.

Key Dates